🇬🇧 United Kingdom Country × Condition
cardiovascular diseases Clinical Trials in United Kingdom
Active clinical trials for cardiovascular diseases with research sites in United Kingdom. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 4 // Recruiting: 4 // Updated: Daily
Total Trials
4
Recruiting Now
4
Country
🇬🇧 United Kingdom
Active Trials in United Kingdom (4)
NCT03049254
Recruiting
Mayo AVC Registry and Biobank
Enrollment
1,000 pts
Country
🇬🇧 United Kingdom
Mayo Clinic
View Trial → NCT06435611
Recruiting
Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups: a Feasibility and Pilot Study
Enrollment
10 pts
Country
🇬🇧 United Kingdom
King's College Hospital NHS Trust
View Trial → NCT03992560
Recruiting
A Prospective Randomised Multi-centre Trial Comparing cArdiac MRI Guided CRT Versus Conventional CRT Implantation in Patients With Ischaemic Cardiomyopathy
Enrollment
218 pts
Country
🇬🇧 United Kingdom
Guy's and St Thomas' NHS Foundation...
View Trial → NCT04193475
Recruiting
Machine Learning in Quantitative Stress Echocardiography
Enrollment
1,250 pts
Country
🇬🇧 United Kingdom
Hull University Teaching Hospitals ...
View Trial → Frequently Asked Questions
How many cardiovascular diseases clinical trials are active in United Kingdom?
There are currently 4 active clinical trials for cardiovascular diseases with sites in United Kingdom, of which 4 are actively recruiting patients.
How can I join a cardiovascular diseases clinical trial in United Kingdom?
To join a cardiovascular diseases clinical trial in United Kingdom, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United Kingdom directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are cardiovascular diseases trials in United Kingdom?
Active cardiovascular diseases trials in United Kingdom span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.